Literature DB >> 9053475

Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma.

M J Watts1, A M Sullivan, E Jamieson, R Pearce, A Fielding, S Devereux, A H Goldstone, D C Linch.   

Abstract

PURPOSE: To define parameters that predict for rapid engraftment after peripheral-blood stem-cell (PBSC) transplantation, progenitor thresholds, the proportion of patients who achieve these thresholds with a standardized mobilization regimen, and the factors that predict for mobilization efficiency. PATIENTS AND METHODS: One hundred and one patients with pretreated lymphoma were mobilized with cyclophosphamide 1.5 g/m2 and granulocyte colony-stimulating factor (G-CSF), with the first apheresis performed when the recovery WBC count was > or = 5.0 x 10(9)/L. The relationship between the number of progenitor cells collected and patient age, sex, diagnosis, prior radiotherapy, and time since last chemotherapy was determined by multivariate analysis. The relationship between these factors, progenitor numbers returned, post-PBSC G-CSF, and hematologic recovery was performed in 81 patients following chemotherapy with carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM protocol).
RESULTS: No BEAM recipients had delayed neutrophil recovery beyond 28 days. Delayed platelet recovery occurred in 7.4% and minimum and optimum thresholds of 1 x 10(6) and 3.5 x 10(6) CD34+ cells/kg and 1 x 10(5) and 3.5 x 10(5) granulocyte-macrophage colony-forming cells (GM-CFC)/kg were established. Hematologic recovery was adversely affected by prior treatment with mini-BEAM, and neutrophil recovery was accelerated by post-PBSC G-CSF. The minimum GM-CFC threshold was achieved with a single apheresis in 83% of patients and in 90% with two aphereses. The optimal threshold was achieved with two leukaphereses in 69% of patients. Prior radiotherapy adversely affected mobilization.
CONCLUSION: Hematopoietic recovery following PBSC is dependent on progenitor-cell number infused and affect of previous chemotherapy on progenitor quality. Progenitor-cell mobilization is adversely affected by prior radiotherapy. The minimum threshold of GM-CFC required is achieved in most patients with a single apheresis, but an optimal collection usually requires at least two harvests.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9053475     DOI: 10.1200/JCO.1997.15.2.535

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission.

Authors:  Jeeyun Lee; Mark H Lee; Keon Woo Park; Jung Hoon Kang; Do Hyung Im; Kihyun Kim; Se-Hoon Lee; Won Seog Kim; Jinny Park; Chul Won Jung; Keunchil Parka
Journal:  Int J Hematol       Date:  2005-04       Impact factor: 2.490

Review 2.  Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 3.  Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

4.  Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo.

Authors:  A Olivieri; M Marchetti; R Lemoli; C Tarella; A Iacone; F Lanza; A Rambaldi; A Bosi
Journal:  Bone Marrow Transplant       Date:  2011-05-30       Impact factor: 5.483

5.  ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients.

Authors:  M J Watts; S J Ings; D Leverett; A MacMillan; S Devereux; A H Goldstone; D C Linch
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor.

Authors:  Gian Paolo Fadini; Mark Fiala; Roberta Cappellari; Marianna Danna; Soo Park; Nicol Poncina; Lisa Menegazzo; Mattia Albiero; John DiPersio; Keith Stockerl-Goldstein; Angelo Avogaro
Journal:  Diabetes       Date:  2015-03-24       Impact factor: 9.461

7.  High-dose versus low-dose cyclophosphamide in combination with G-CSF for peripheral blood progenitor cell mobilization.

Authors:  Jin Seok Ahn; Seonyang Park; Seock-Ah Im; Sung-Soo Yoon; Jong-Seok Lee; Byoung Kook Kim; Soo-Mee Bang; Eun Kyung Cho; Jae Hoon Lee; Chul Won Jung; Hugh Chul Kim; Chu Myung Seong; Moon Hee Lee; Chul Soo Kim; Keun Seok Lee; Jung Ae Lee; Myung-Ju Ahn
Journal:  Korean J Intern Med       Date:  2005-09       Impact factor: 2.884

8.  Timing of peripheral blood stem cell yield: comparison of alternative methods with the classic method for CD34+ cell determination.

Authors:  I Fatorova; M Blaha; M Lanska; D Vokurkova; V Rezacova; P Zak
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.